StockNews.AI
EXEL
StockNews.AI
60 days

Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

1. Exelixis partner Ipsen receives positive EMA opinion for CABOMETYX®. 2. CABOMETYX® is indicated for advanced neuroendocrine tumors after prior therapies.

2m saved
Insight
Article

FAQ

Why Bullish?

The EMA's positive opinion for CABOMETYX® can enhance sales and market opportunities. Similar past approvals have resulted in stock price increases for biopharma companies.

How important is it?

The positive EMA opinion directly affects EXEL's growth potential and revenue streams from CABOMETYX®, enhancing investor confidence.

Why Long Term?

Positive regulatory opinions typically lead to increased market access and revenue growth over time. A similar situation occurred with other drugs achieving EMA approval, resulting in sustained price uplifts.

Related Companies

IPNJNJAMGN
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for CABOMETYX® (cabozantinib) for adult patients with unresectable or metastatic, well-differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.

Related News